Ship Finance International Limited (NYSE:SFL) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it 1.52% to close at $14.73 with the total traded volume of 2.29 Million shares. Ship Finance International Limited (SFL) reported that it has surged the size of the public offering of its Convertible Senior Notes due 2021 reported September 29, 2016 by $25 million, to a total of $225 million aggregate principal amount.
In addition, Ship Finance reported the pricing of its offering of $225 million aggregate principal amount of the Notes. The Notes will pay interest quarterly in arrears at a rate of 5.75% per annum and will mature on October 15, 2021, unless earlier repurchased, redeemed or converted.
The Notes will be convertible, at any time previous to the close of business on the second planned trading day previous to the maturity date, into, cash, our ordinary shares, or a combination of cash and our ordinary shares, at the Firm’s election, as additional described in the offering prospectus.
The conversion rate for the Notes will initially be 56.2596 ordinary of our ordinary shares per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of about $17.77 per ordinary share, and is subject to adjustment under the terms of the Notes. The firm has institutional ownership of 61.10%, while insider ownership included 43.40%. Its price to sales ratio ended at 3.04. SFL attains analyst recommendation of 2.90 with week performance of 0.27%.
Emergent BioSolutions, Inc. (NYSE:EBS) [Trend Analysis] climbed reacts as active mover, shares a gain 13.58% to traded at $31.53 and the percentage gap among open changing to regular change was 7.82%. Emergent BioSolutions Inc. (EBS) provided an update on the status of its 2011 BioThrax (Anthrax Vaccine Adsorbed) procurement contract and the status of its discussions with the Centers for Disease Control and Prevention (CDC) for a follow-on procurement contract for BioThrax.
The 2011 Procurement Contract: CDC has exercised an option to procure all remaining BioThrax doses, thereby committing to take delivery of the full 44.75 million doses, under the procurement contract reported on October 3, 2011 and due to expire September 30, 2016. In concert with this option exercise, CDC has granted a no-cost extension to enable delivery of the remaining doses to be completed by November 30, 2016. The firm’s current ratio calculated as 5.10 for the most recent quarter. The firm past twelve months price to sales ratio was 2.06 and price to cash ratio remained 3.37. As far as the returns are concern, the return on equity was recorded as 9.70% and return on investment was 7.60% while its return on asset stayed at 6.20%. The firm has total debt to equity ratio measured as 0.37.